Cortice Biosciences
Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer’s Disease and Related Tauopathies
November 03, 2017 09:00 ET | Cortice Biosciences
–  Possible evidence of clinical activity in Alzheimer’s disease patients treated with TPI 287 – – Drug administration was generally well-tolerated – – Results support further exploration of TPI 287...
Cortice Biosciences
Cortice Biosciences Announces Presentation of Final Results from the Dose Escalation Stage of a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma
June 05, 2017 09:00 ET | Cortice Biosciences
– 13.4 month median overall survival; 64% of patients alive after one year – – 60% objective response rate; 96% disease stabilization rate – – Clinical outcomes and biomarker data...
Cortice Biosciences
Cortice Biosciences Announces an Upcoming Presentation at the 2017 American Society of Clinical Oncology Annual Meeting
May 18, 2017 09:00 ET | Cortice Biosciences
NEW YORK, May 18, 2017 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that final results from the dose-escalation portion of a Phase 1/2 clinical trial evaluating TPI 287 for treatment of...
Cortice Biosciences
Cortice Biosciences Announces Presentation of Results from a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma at the 21st Annual Scientific Meeting of the Society of Neuro-Oncology
November 18, 2016 09:00 ET | Cortice Biosciences
–  Median overall survival improved to 13.4 from 12.9 months after extended follow-up  – –  64% of patients alive after one year compared to historical rates of 25-38%   – –...
Cortice Biosciences
Cortice Biosciences Announces Presentation of Results from a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma at the Annual Meeting of the American Society of Clinical Oncology
June 03, 2016 10:06 ET | Cortice Biosciences
–  60% overall response rate; 96% achieved stable disease or better – –  12.9 mo. median and 60% 1-year overall survival in combination with Avastin® –   – Safety profile remains...
Cortice Biosciences
Cortice Biosciences Announces Updated Results From Clinical Trials Evaluating TPI 287 for Treatment of Brain Malignancies
November 20, 2015 09:45 ET | Cortice Biosciences
– 60% overall response rate; 12.9 month median and 71% 12-month overall survival in combination with Avastin® for treatment of recurrent glioblastoma –   – Complete response and stable disease...
Cortice Biosciences
Cortice Biosciences Announces Upcoming Presentations at the 20th Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day
November 09, 2015 10:41 ET | Cortice Biosciences
NEW YORK, Nov. 09, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that results from on-going clinical trials evaluating TPI 287 for treatment of brain cancers will be presented at the...
Cortice Biosciences
Cortice Biosciences Announces Issuance of a Key Patent Covering the Company's Alzheimer's Disease Drug Development Program
July 08, 2015 10:00 ET | Cortice Biosciences
NEW YORK, July 08, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that Patent No. 9,072,746, “Method for Enhancing Learning and Memory Impaired by Neurodegenerative Disorders and...
Cortice Biosciences
Cortice Biosciences to Present at Upcoming Conferences
May 26, 2015 10:11 ET | Cortice Biosciences
NEW YORK, May 26, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences, a clinical-stage drug development company pioneering novel therapies for oncologic and neurologic disease indications with urgent...
Cortice Biosciences
Cortice Biosciences Announces Updated Results From a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma
April 21, 2015 09:26 ET | Cortice Biosciences
  – 56% objective response rate in 16 evaluable patients treated with TPI 287 plus Avastin® –  – Overall survival results maturing: median 12.6 months; 73% alive at 9 months, 67% alive at...